Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price traded up 31% on Thursday . The stock traded as high as C$0.24 and last traded at C$0.19. 727,200 shares changed hands during trading, an increase of 59% from the average session volume of 456,000 shares. The stock had previously closed at C$0.15.
Hemostemix Stock Performance
The firm has a fifty day moving average of C$0.09 and a 200-day moving average of C$0.07. The stock has a market capitalization of C$16.55 million, a price-to-earnings ratio of -9.50 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- The How and Why of Investing in Gold Stocks
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- Best Stocks Under $10.00
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
